Published on 21/12/2025
First-in-Human Trials in China: Regulatory Pathways and Case Insights
Introduction
First-in-Human (FIH) trials mark a critical milestone in clinical development, testing a new investigational product in humans for the first time. In China, the conduct of FIH trials has evolved significantly, reflecting regulatory reforms, site capacity building, and harmonization with International Council for Harmonisation (ICH) standards. Once constrained by limited infrastructure and lengthy approvals under the former CFDA, China’s National Medical Products Administration (NMPA) now oversees a robust framework that supports safe, compliant, and globally relevant early-phase research. This article examines the regulatory environment for FIH trials in China, core operational insights, and illustrative case studies that highlight both achievements and ongoing challenges.
Background and Regulatory Framework
Historic Constraints on Early-Phase Trials
Under the CFDA, FIH trials faced extended approval timelines and limited accredited Phase I units. Only a handful of Tier-1 hospitals could conduct these studies, leading to delays and restricted access for multinational sponsors. Safety concerns and data integrity issues further constrained confidence in early-phase Chinese trials.
NMPA Reforms Supporting FIH Trials
The establishment of the NMPA introduced a 60-working-day “silent approval” system for INDs, reducing trial initiation timelines. The 2019 Drug Administration Law strengthened requirements for
Case Example: Oncology FIH Trial
A 2020 oncology FIH trial was approved under the NMPA silent approval system, enrolling patients in Shanghai within three months. The trial successfully generated PK/PD data comparable to global benchmarks, demonstrating the effectiveness of China’s reformed early-phase framework.
Core Clinical Trial Insights
IND Requirements for FIH Trials
An FIH IND submission to the NMPA must include:
✔️ Preclinical toxicology and pharmacology data
✔️ Chemistry, Manufacturing, and Controls (CMC) information
✔️ Investigator’s Brochure and trial protocol
✔️ Ethics committee approvals
The silent approval system allows trials to proceed if no objections are raised within 60 working days.
Site Accreditation and Capacity
FIH trials may only be conducted at accredited Phase I units. Requirements include emergency response facilities, trained investigators, validated laboratories, and data management systems. Tier-1 hospitals lead FIH capacity, but Tier-2 hospitals are increasingly expanding their early-phase units with CRO support.
Safety and Pharmacovigilance
FIH trials require intensive safety monitoring, with sponsors mandated to report adverse events within strict timelines. Pharmacovigilance obligations are outlined in the 2019 Drug Administration Law and aligned with ICH E2E. Safety committees must review dose-escalation decisions before patient progression.
Ethics Oversight
Ethics committees must ensure informed consent is comprehensible and risks are clearly communicated. The NMPA requires eConsent systems to include audit trails where used, particularly for high-risk FIH studies. Centralized ethics reviews are being piloted to standardize oversight across sites.
Multinational Integration
Global sponsors increasingly include Chinese sites in multinational FIH programs, particularly in oncology and biologics. Inclusion allows Chinese patients early access to innovative therapies while generating globally relevant PK/PD data. Harmonized protocols are essential to ensure comparability with FDA and EMA submissions.
Challenges in Conducting FIH Trials
Key challenges include:
✔️ Limited Phase I infrastructure in Tier-2 hospitals
✔️ High competition for experienced investigators
✔️ Strict data localization requirements for genetic and safety data
✔️ Fragmented ethics reviews in some regions
Sponsors must plan carefully to overcome these hurdles.
Best Practices & Preventive Measures
Sponsors should engage the NMPA early through pre-IND consultations, select accredited Phase I units with strong safety infrastructure, and implement robust pharmacovigilance systems. CRO partnerships are essential for operational support, particularly in site readiness and data management. Early patient advocacy engagement improves recruitment and trust in high-risk early-phase studies.
Scientific & Regulatory Evidence
The NMPA’s FIH framework reflects ICH E6(R2) GCP, ICH E5 on ethnic sensitivity, and WHO safety guidelines. Comparative evidence shows China’s timelines now align with FDA and EMA Phase I standards, with similar safety and ethics obligations. The 2019 Drug Administration Law codifies pharmacovigilance responsibilities, elevating China’s regulatory rigor for FIH studies.
Special Considerations
FIH trials in rare diseases and pediatrics face unique ethical and logistical challenges. Sponsors must provide enhanced safety monitoring and ensure robust justification for early human exposure. Trials involving genetic samples also require Human Genetic Resources Administration of China (HGRAC) approval, adding another layer of regulatory oversight.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek NMPA advice during the pre-IND phase to clarify expectations for safety data, site requirements, and pharmacogenomic considerations. Mid-trial consultations are recommended when dose-escalation or protocol modifications are needed. CROs and investigators should also engage regulators early to ensure inspection readiness.
Case Studies
Case Study 1: Oncology FIH Trial in Shanghai
A global biotech sponsor conducted a Phase I oncology trial in Shanghai, gaining approval in under 75 working days. The trial’s safety and PK data were accepted by both the FDA and EMA, enabling simultaneous global submissions. This case highlights China’s growing role in FIH oncology research.
Case Study 2: FIH Biologics Trial in Beijing
A biologics sponsor initiated an FIH study in healthy volunteers at a Beijing Phase I unit. The trial used eConsent with video modules and achieved high patient comprehension rates. NMPA inspectors confirmed compliance, setting a precedent for future eConsent use in high-risk early-phase studies.
FAQs
1. What are First-in-Human trials?
They are Phase I studies where a new investigational drug is tested in humans for the first time to assess safety, PK, and PD.
2. How long does it take to get FIH approval in China?
Under the silent approval system, FIH INDs are typically approved within 60 working days, comparable to global benchmarks.
3. Where can FIH trials be conducted in China?
Only at accredited Phase I units with the necessary infrastructure, trained staff, and emergency care capacity.
4. How are safety concerns managed in FIH trials?
Through intensive monitoring, pharmacovigilance systems, and ethics oversight. Adverse events must be reported promptly under NMPA rules.
5. Are FIH trials in China accepted globally?
Yes, provided data meet ICH, FDA, and EMA standards. Including Chinese patients in global FIH trials supports multinational submissions.
6. What role do CROs play in FIH trials?
CROs support site readiness, data management, and regulatory compliance, ensuring smooth execution of complex early-phase studies.
Conclusion & Call-to-Action
FIH trials in China have progressed from lengthy, restricted processes to a globally competitive framework under the NMPA. With streamlined approvals, improved site capacity, and harmonized regulations, China is now a valuable contributor to multinational early-phase development. Sponsors should prioritize accredited sites, strong CRO partnerships, and early NMPA consultations to ensure compliance and efficiency. Organizations planning FIH studies should integrate China into their global development strategies to leverage its patient access and regulatory reforms.